Drugs / CT103A
CT103A
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT04561557 | Sep 2020 → Feb 2027 expected | POEMS syndrome, autoimmune encephalitis, chronic inflammatory demyelinating polyradiculoneuropathy, idiopathic inflammatory myopathy +4 | Tongji Hospital | Recruiting | No outcome recorded |
| Phase 12 trials | ||||||
| Phase 1 | NCT05181501 | Apr 2022 → Apr 2024 overdue | plasma cell myeloma | Nanjing IASO Biotechnology Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT05201118 | Jan → Dec 2022 | plasma cell myeloma | Chunrui Li | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05066646 | Apr 2020 → Oct 2022 | plasma cell myeloma | Nanjing IASO Biotechnology Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CT103A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05066646 ↗ |
| Known as | Equecabtagene Autoleucel | “Equecabtagene autoleucel (Fucaso®), an autologous anti-B cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR)-T cell therapy” PMID 37658205 ↗ Sep 2023 |
| Known as | Fucaso | “Equecabtagene autoleucel (Fucaso®), an autologous anti-B cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR)-T cell therapy” PMID 37658205 ↗ Sep 2023 |
| Action | Deplete | “to eliminate plasma cells in patients with neurological autoimmune diseases driven by abnormal antibody” NCT04561557 ↗ |
| Modality | Cell therapy | “novel CAR-T cell therapy using CT103A cells” NCT04561557 ↗ |
| Route | Intravenous | “receive one dose treatment with CT103A cells by intravenous (IV) infusion” NCT04561557 ↗ |